Literature DB >> 17412709

Evidence-based therapeutics--introducing the Cochrane corner.

William T Carpenter1, Gunvant K Thaker.   

Abstract

Mesh：

Year:  2007        PMID： 17412709      PMCID： PMC2526134          DOI： 10.1093/schbul/sbm027

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  3 in total

Review 1.  Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review.

Authors:  L Duggan; J Brylewski
Journal:  J Intellect Disabil Res       Date:  1999-04

2.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Authors:  Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis
Journal:  Arch Gen Psychiatry       Date:  2006-10

3.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245
  3 in total
  2 in total

Review 1.  Cochrane Schizophrenia Group.

Authors:  Clive E Adams; Evandro S F Coutinho; John Davis; Lorna Duggan; Stefan Leucht; Chunbo Li; Prathap Tharyan
Journal:  Schizophr Bull       Date:  2008-01-31       Impact factor: 9.306

Review 2.  Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Authors:  Rodrigo D Paz; Sonia Tardito; Marco Atzori; Kuei Y Tseng
Journal:  Eur Neuropsychopharmacol       Date:  2008-07-23       Impact factor: 4.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.